VolitionRx announces pricing of $1.2M registered direct offering

VolitionRx (VNRX) Limited announced that it has entered into definitive agreements for the purchase and sale of (i) 156K shares of its common stock to certain directors and executive officers of the company at an offering price of 64c per share, and (ii) 1.73M shares of its common stock, together with common stock purchase warrants to purchase up to 1.73M shares of common stock, to certain other existing stockholders of the company at a combined offering price of 64c per share and accompanying warrant. Each warrant has an exercise price per share of 76.8c, and is exercisable immediately upon issuance, and expires five years from the issuance date. The insiders will not receive any Warrants in the offering. The securities will be issued and sold in the offering by the company directly to the investors and without a placement agent. The offering is expected to close on or about August 5, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds from the offering to the company are expected to be $1.21M, before deducting estimated offering expenses payable by the company, assuming no exercise of the warrants.